Evidence map›Paper›PMID 33740467›Full record

ArticleThe Lancet. Respiratory medicine2021

A leap forward in assessing host-directed therapies for tuberculosis.

Elisa H Ignatius, Kelly E Dooley

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Elisa H IgnatiusDivisions of Infectious Diseases and Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Kelly E DooleyDivisions of Infectious Diseases and Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address: kdooley1@jhmi.edu.

Funding

Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4M
Optimizing Anti-mycobacterial Therapy Using A Pharmacology-based ApproachK23AI159145 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Elisa Helen Ignatius · 2022 to 2026
$994k
Mentoring Investigators in HIV and Tuberculosis Therapeutics ResearchK24AI150349 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DOOLEY, KELLY E. · 2020 to 2025
$789k
NIAID NIH HHS K23 AI159145NIAID NIH HHS K24 AI150349NIGMS NIH HHS T32 GM066691
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Mycobacterium tuberculosisTuberculosisHumans

Identifiers

PMID33740467
PMCPMC9190060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.